Skip to main content

Verso ACC.22: i Late-Breaking Clinical Trials

Redazione By 25 Marzo 2022Marzo 29th, 2022No Comments
Dai congressi
ACC.22 Clinical trials

Mancano pochi giorni all’inizio dell’edizione 2022 del meeting annuale dell’American College of Cardiology (ACC.22), in programma dal 2 al 4 aprile presso il Walter E. Washington Convention Center di Washington. L’evento, uno dei più importanti al mondo in ambito cardiologico, riapre alla partecipazione in presenza (previa dimostrazione del completamento del ciclo vaccinale) dopo due edizioni tenutesi esclusivamente in formato virtuale a causa della pandemia di COVID-19, ma le sessioni saranno disponibili anche da remoto.

In attesa della cerimonia inaugurale, ecco la lista dei Late-Breaking Clinical Trials che saranno presentati e discussi nel corso delle tre giornate congressuali di ACC.22:

Sabato 2 aprile, 15:30-16:30 (9:30-10:30 a.m. ET)

Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials:

  • VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
  • SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
  • The POISE-3 Trial: Efficacy and Safety of Tranexamic Acid in Patients Undergoing Noncardiac Surgery
  • CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT
Domenica 3 aprile, 14:00-15:15 (8:00-9:15 a.m. ET)

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials:

  • MITIGATE: A Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults in an Era of Coronavirus Disease 2019
  • TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-high-density Lipoprotein Cholesterol Levels In Statin-treated Patients With Elevated Cholesterol
  • PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial
  • APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial
  • SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular Risk Reduction
Domenica 3 aprile, 15:45-17:00 (9:45-11:00 a.m. ET)

Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials:

  • IVVE: Randomized Controlled Trial of Influenza Vaccine in Patients With Heart Failure to Reduce Adverse Vascular Events
  • METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance in Patients With Chronic Heart Failure and Reduced Ejection Fraction
  • PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs With Heart Failure
  • DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction
  • Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients With Obstructive Hypertrophic Cardiomyopathy
Lunedì 4 aprile, 14:30-15:45 (8:30-9:45 a.m. ET)

Late-Breaking Clinical Trials IV:

  • The PROTECT Trial: Very Mild Perioperative Hypothermia Versus Aggressive Warming and Myocardial Injury After Non-cardiac Surgery
  • POISE-3: The Effects of a Hypotension-avoidance Strategy Versus a Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery
  • One-year Results of the Clasp TR Study: Transcatheter Treatment of Tricuspid Regurgitation
  • Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
  • A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement